STADA Arzneimittel AG — Earnings Release 2003

May 20, 2003

News Details

Ad-hoc | 20 May 2003 08:00

STADA Arzneimittel AG english

STADA: Excellent Start. Record Result Q1 2003 Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA: Excellent Start. Record Result Q1 2003 In the first quarter of 2003 (Q1 2003), STADA increased its consolidated sales by +19% from Q1 2002 to EUR 181.2 million; sales in the three core segments generics, branded products and special pharmaceuticals grew by a total of +33% to EUR 172.2 million (individually: generics +32%, branded products +32%, special pharmaceuticals +42%). The non-core commercial business segment declined by another -66% as planned. This means the core segments now contributed 95% of total sales. In earnings, too, STADA recorded new all-time highs in Q1 2003. The Groups net income increased to EUR 12.4 million in Q1 2003 (+11.4%), earnings before taxes (EBT) to EUR 21.7 million (+15.0%) and earnings before interest and taxes (EBIT) to EUR 25.2 million (+19.3%). In Q1 2003, EBITDA was EUR 34.1 million (+30.8%) due to the higher amortization of intangible assets in connection with the active acquisition policy. The earnings per share reached EUR 0.62 in Q1 2003 (Q1 2002: EUR 0.60 with 6.3% fewer shares) and diluted earnings per share (according to IAS) were EUR 0.60 (Q1 2002: EUR 0.50). Geographically, the growth was established on a broad basis. Many national STADA sales companies were able to expand their sales in Q1 2003, in some instances very strongly – for instance, in France (+78%), Italy (+224%), Spain (+1,965%), the USA (+39%) and Germany (+15%). The sales efforts in growth markets were further intensified in Q1 2003 and led to a rise in the cost of sales ratio to 25.9% (Q1 2002: 24.7%). On the whole, the first quarter of 2003 was the best quarter in the Companys history. From the perspective of the Executive Board, this confirms the target for the current financial year to become the 8th record year in a row with growth in sales and profits in the double-digit percentage range. You will find the complete quarterly report on the Internet at http://www.stada.com . Additional information: STADA Arzneimittel AG / Corporate Communications / 61118 Bad Vilbel / Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de / Internet: http://www.stada.com end of ad-hoc-announcement (c)DGAP 20.05.2003 ——————————————————————————– WKN: 725180; ISIN: DE0007251803; Index: MDAX Listed: Amtlicher Markt in Düsseldorf und Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Hamburg, Hannover, München und Stuttgart 200800 Mai 03